{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:38:24Z","timestamp":1778884704022,"version":"3.51.4"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate which fluoroquinolone is safer when combined with bedaquiline for tuberculosis treatment by using the FDA Adverse Event Reporting System (FAERS) database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We selected data from the first quarter (Q1) of 2013 to the second quarter (Q4) of 2024 from the FDA FAERS database for disproportionality analysis. Signal detection was conducted using the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayesian Geometric Mean (EBGM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This study analyzed 12, 303, 879 reports from the FAERS database, including 722 reports related to the combination of bedaquiline and levofloxacin (with 2,723 adverse events) and 573 reports related to the combination of bedaquiline and moxifloxacin (with 2,233 adverse events). For the bedaquiline-levofloxacin regimen, these reports were categorized into 100 preferred terms (PTs) and 24 System Organ Classification (SOCs). The three most common SOCs were hepatobiliary disorders (n = 128, ROR 5.79, PRR 5.56, IC 2.48, EBGM 5.56), blood and lymphatic system disorders (n = 217, ROR 5.04, PRR 4.72, IC 2.24, EBGM 4.71), and metabolism and nutrition disorders (n = 185, ROR 3.44, PRR 3.27, IC 1.71, EBGM 3.27). In terms of PTs, the three strongest signals were portal fibrosis (ROR 330.64), hepatitis C RNA increased (ROR 301.24), and toxic optic neuropathy (ROR 238.11). Reports of prolonged QT interval on ECG (125 cases) and anemia (130 cases) were significantly more frequent than other PTs. For the bedaquiline-moxifloxacin regimen, these reports were categorized into 85 preferred terms (PTs) and 24 System Organ Classification (SOCs). The three most common SOCs were hepatobiliary disorders (n = 141, ROR 7.9, PRR 7.47, IC 2.9, EBGM 7.46), ear and labyrinth disorders (n = 40, ROR 4.03, PRR 3.97, IC 1.99, EBGM 3.97), and cardiac disorders (n = 141, ROR 3.08, PRR 2.95, IC 1.56, EBGM 2.95). The three strongest PT signals were chronic pyelonephritis (ROR 563.29), bronchopleural fistula (ROR 314.86), and toxic neuropathy (ROR 187.11). Prolonged QT interval on ECG (152 cases) remained the most frequently reported PT. In both treatment regimens, individuals under 45\u00a0years of age experienced a higher frequency and variety of AEs, indicating the need for enhanced monitoring. For those over 45, particular attention should be given to ECG changes, especially in men. Finally, some PTs with extremely high signal strength, such as chronic pyelonephritis (ROR 563.29), hepatitis C RNA increased (ROR 301.24), and bronchopleural fistula (ROR 301.24), may represent rare adverse events associated with the combination of bedaquiline-fluoroquinolone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study suggests that the safety profile of bedaquiline combined with moxifloxacin does not appear superior to that of bedaquiline combined with levofloxacin in terms of cardiac, hepatic, and neurological effects. Therefore, in the BPaLM regimen, considering the substitution of moxifloxacin with levofloxacin may be worthwhile if their efficacy is proven to be similar. Increased monitoring may be required for individuals under 45\u00a0years of age and male MDR-TB patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1491921","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T09:17:38Z","timestamp":1733995058000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Which fluoroquinolone is safer when combined with bedaquiline for tuberculosis treatment: evidence from FDA Adverse Event Reporting System database from 2013 to 2024"],"prefix":"10.3389","volume":"15","author":[{"given":"Sheng","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changping","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanlang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12941-016-0156-y","article-title":"Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis","volume":"15","author":"Agyeman","year":"2016","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"B2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.annepidem.2013.12.009","article-title":"Peripheral neuropathy and Guillain-Barr\u00e9 syndrome risks associated with exposure to systemic fluoroquinolones: a pharmacovigilance analysis","volume":"24","author":"Ali","year":"2014","journal-title":"Ann. Epidemiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.mcna.2018.10.006","article-title":"Peripheral neuropathy","volume":"103","author":"Barrell","year":"2019","journal-title":"Med. Clin. North Am."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1080\/14740338.2019.1665022","article-title":"An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms\/dissections disseminated by the Food and Drug Administration and the European Medicines Agency","volume":"18","author":"Bennett","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"B5","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1212\/WNL.0000000000002455","article-title":"Antibiotic-associated encephalopathy","volume":"86","author":"Bhattacharyya","year":"2016","journal-title":"Neurology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000334441","article-title":"QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications","volume":"120","author":"Briasoulis","year":"2011","journal-title":"Cardiology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"S308","DOI":"10.1093\/cid\/ciy624","article-title":"D-cycloserine pharmacokinetics\/pharmacodynamics, susceptibility, and dosing implications in multidrug-resistant tuberculosis: a faustian deal","volume":"67","author":"Deshpande","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3390\/medicina58020188","article-title":"MDR tuberculosis treatment","volume":"58","author":"Espinosa-Pereiro","year":"2022","journal-title":"Med. Kaunas."},{"key":"B9","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1093\/cid\/ciy416","article-title":"Clinical and cardiac safety of long-term levofloxacin in children treated for multidrug-resistant tuberculosis","volume":"67","author":"Garcia-Prats","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1365-2125.2011.03991.x","article-title":"Neurotoxic effects associated with antibiotic use: management considerations","volume":"72","author":"Grill","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1086\/598929","article-title":"Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens","volume":"48","author":"Ho","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3390\/ph15020143","article-title":"A VigiBase descriptive study of fluoroquinolone-associated peripheral nervous system disorders","volume":"15","author":"Huruba","year":"2022","journal-title":"Pharm. (Basel)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3109\/15376516.2015.1026008","article-title":"Ciprofloxacin-induced neurotoxicity: evaluation of possible underlying mechanisms","volume":"25","author":"Ilgin","year":"2015","journal-title":"Toxicol. Mech. Methods"},{"key":"B15","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2165\/11593110-000000000-00000","article-title":"Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review","volume":"34","author":"Jones","year":"2011","journal-title":"Drug Saf."},{"key":"B16","first-page":"23","article-title":"Multidrug-resistant tuberculosis","volume":"10","author":"Keertan Dheda","year":"","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1080\/14740338.2018.1520837","article-title":"Moxifloxacin-induced QT interval prolongation and torsades de pointes: a narrative review","volume":"17","author":"Khan","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"B18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1136\/postgradmedj-2020-138661","article-title":"Managing drug-induced QT prolongation in clinical practice","volume":"97","author":"Khatib","year":"2021","journal-title":"Postgrad. Med. J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e0104823","DOI":"10.1128\/spectrum.01048-23","article-title":"Effects of bedaquiline combined with fluoroquinolone and\/or clofazimine on QT interval in patients with multidrug-resistant tuberculosis: a retrospective study","volume":"11","author":"Li","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.clinthera.2014.09.020","article-title":"Neurotoxicity with antimicrobials in the elderly: a review","volume":"36","author":"Mattappalil","year":"2014","journal-title":"Clin. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e10507","DOI":"10.7759\/cureus.10507","article-title":"Moxifloxacin-induced thrombocytopenia mediated by moxifloxacin-dependent IgM and IgG antiplatelet antibodies: a case report","volume":"12","author":"Moore","year":"2020","journal-title":"Cureus"},{"key":"B22","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jamaneurol.2019.0887","article-title":"Association between peripheral neuropathy and exposure to oral fluoroquinolone or amoxicillin-clavulanate therapy","volume":"76","author":"Morales","year":"2019","journal-title":"JAMA Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/ejhpharm-2018-001805","article-title":"Seizures and quinolone antibiotics in children: a systematic review of adverse events","volume":"27","author":"Neame","year":"2020","journal-title":"Eur. J. Hosp. Pharm."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1093\/cid\/ciab825","article-title":"Oral fluoroquinolone use and the risk of acute liver injury: a nationwide cohort study","volume":"74","author":"Nibell","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/j.hrthm.2015.07.011","article-title":"Consistency of heart rate-QTc prolongation consistency and sudden cardiac death: the Rotterdam Study","volume":"12","author":"Niemeijer","year":"2015","journal-title":"Heart rhythm."},{"key":"B26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.tube.2019.06.005","article-title":"A structural insight of bedaquiline for the cardiotoxicity and hepatotoxicity","volume":"117","author":"Patel","year":"2019","journal-title":"Tuberc. (Edinb)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B28","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.toxlet.2018.05.032","article-title":"Isoniazid-induced hepatotoxicity and neurotoxicity in rats investigated by 1H NMR based metabolomics approach","volume":"295","author":"Ruan","year":"2018","journal-title":"Toxicol. Lett."},{"key":"B29","doi-asserted-by":"publisher","first-page":"272","DOI":"10.12659\/ajcr.907440","article-title":"A case of levofloxacin-induced hepatotoxicity","volume":"19","author":"Schloss","year":"2018","journal-title":"Am. J. Case Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"201015","DOI":"10.1155\/2014\/201015","article-title":"Autoimmune hemolytic anemia induced by levofloxacin","volume":"2014","author":"Sheikh-Taha","year":"2014","journal-title":"Case Rep. Infect. Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/jcpt.12596","article-title":"Ciprofloxacin-induced immune-mediated thrombocytopenia: No cross-reactivity with gemifloxacin","volume":"43","author":"Sim","year":"2018","journal-title":"J. Clin. Pharm. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"7250","DOI":"10.1128\/AAC.03728-14","article-title":"Properties of AdeABC and AdeIJK efflux systems of Acinetobacter baumannii compared with those of the AcrAB-TolC system of Escherichia coli","volume":"58","author":"Sugawara","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.11622\/smedj.2014111","article-title":"Drug-induced immune haemolytic anaemia caused by levofloxacin","volume":"55","author":"Sukhal","year":"2014","journal-title":"Singap. Med. J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/jgh3.12585","article-title":"Systemic quinolones and risk of acute liver failure I: analysis of data from the US FDA adverse event reporting system","volume":"5","author":"Taher","year":"2021","journal-title":"JGH Open"},{"key":"B35","article-title":"It\u2019s time to end drug-resistant tuberculosis","year":"2019","journal-title":"Econ"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3390\/antibiotics12091389","article-title":"The efficacy and safety of bedaquiline in the treatment of pulmonary tuberculosis patients: a systematic review and meta-analysis","volume":"12","author":"Tong","year":"2023","journal-title":"Antibiot. (Basel)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1542-474X.2006.00082.x","article-title":"Effects of three fluoroquinolones on QT analysis after standard treatment courses","volume":"11","author":"Tsikouris","year":"2006","journal-title":"Ann. Noninvasive Electrocardiol."},{"key":"B38","volume-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment","year":"2019"},{"key":"B39","volume-title":"WHO consolidated guidelines on tuberculosis: module 4: treatment - Drug-susceptible tuberculosis treatment","year":""},{"key":"B40","volume-title":"Global tuberculosis report 2022","year":"2022"},{"key":"B41","first-page":"4","volume-title":"WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment","year":"2020"},{"key":"B42","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/j.1440-1843.2006.00941.x","article-title":"Antituberculosis drugs and hepatotoxicity","volume":"11","author":"Yew","year":"2006","journal-title":"Respirology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.2147\/IDR.S365371","article-title":"Linezolid-associated neuropathy in patients with MDR\/XDR tuberculosis in shenzhen, China","volume":"15","author":"Zhang","year":"2022","journal-title":"Infect. Drug Resist"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e19266","DOI":"10.2196\/19266","article-title":"Complementing the US food and drug administration adverse event reporting system with adverse drug reaction reporting from social media: comparative analysis","volume":"6","author":"Zhou","year":"2020","journal-title":"JMIR Public Health Surveill."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","article-title":"Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database","volume":"15","author":"Zou","year":"2024","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1491921\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T09:17:43Z","timestamp":1733995063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1491921\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":45,"alternative-id":["10.3389\/fphar.2024.1491921"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1491921","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]},"article-number":"1491921"}}